The Peptide NewsroomPeptide research, industry and supply-chain headlines

Hims & Hers Launches Peptides+ Longevity Platform Nationwide, But No Trial Data Comes With It

Topic card: safety

Hims & Hers Health has launched its Peptides+ longevity platform across the United States through its telehealth service, according to a Simply Wall St analysis published on Yahoo Finance. The offering bundles compounded peptide and nutrient therapies into a subscription-style program with at-home blood collection and ongoing clinical oversight.

The named ingredients are sermorelin, NAD+, glutathione, vitamin B-12 and L-carnitine. Sermorelin is the only peptide in that list, and the rest are the standard furniture of the longevity clinic menu, which tells you something about how the category is being assembled.

A subscription tier, not a product

The structure is the interesting part. Peptides+ is described as a personalized program layered onto Care+ lab panels and at-home diagnostics, which makes it a recurring specialty rather than a single line item on a storefront.

That matters commercially because Hims & Hers already reaches nearly 3 million subscribers across multiple conditions, per the analysis. Adding a higher-complexity tier to an existing telehealth and lab stack is a cheaper growth path than acquiring new customers, and the company is clearly betting that longevity is the tier people will pay up for.

The numbers investors will actually watch

The analysis points to a 2026 revenue outlook of US$3.13 billion to US$3.15 billion and almost 2.8 million subscribers as the near-term check on whether this lands. The specific disclosure worth waiting for is peptide subscriber counts or Care+ attachment rates in upcoming earnings commentary.

The same piece flags legal scrutiny and a business mix that can pressure margins as live risks sitting alongside the launch. Compounded therapies have been a regulatory flashpoint for this company before, and a longevity menu does not make that quieter.

What the announcement does not include

No trial, no outcome figure, no published data on any of the five compounds appears anywhere in the coverage. For a program sold on cellular health and longevity, that is a large claim riding on an ingredient list.

It is also worth noting what the source is: a Simply Wall St article produced with AI automation, written for investors rather than patients.

Bottom line

As a business move this is coherent, and the subscription logic is sound. As evidence that peptide-based longevity programs do anything, the launch is not evidence at all, and nothing in the announcement pretends otherwise.

Source: RSS.app — Renewal bundle. Read the original.

Filed under: safety

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Karnataka Regulators Cancel a Bengaluru Peptide Party as India's Longevity Market Accelerates

Karnataka's drug regulator canceled a Bengaluru "Peptide Party" on August 29 and questioned the organizers about ingredients, legality and health claims. The Indian Express reports the shutdown against a biohacking market Grand View Research valued at $1.21 billion in 2025.

Engineered ICOSL Peptide Cuts Proteinuria in Mice, But No Human Trials Yet

Researchers engineered a 19-amino-acid peptide from inducible co-stimulator ligand that blocks alpha-v-beta-3 integrin on kidney podocytes, reducing urinary protein across several rodent models. The work is entirely preclinical, tested a single dose, and human trials have not begun.

Hims and Hers Launches Five Compounded Peptide Treatments With No FDA-Approved Formulations

Hims & Hers has launched five compounded peptide and longevity treatments through a new Peptides+ telehealth platform, none of them FDA-approved. The company's own chief medical officer concedes the usual clinical data is missing, and outside researchers say dosing standards have not been established.